Investigating how targeting Nell2 and GABA dysfunction can help Alzheimer's patients with the APOE4 gene.
Official title: Targeting Nell2 and GABAergic Dysfunction to Mitigate APOE4-Driven Pathogenesis in Alzheimer's Disease
Funded at J. David Gladstone Institutes · NIH-11100623 · Data updated 2026-11-12
This study is looking at how a gene called APOE4, which is linked to Alzheimer's disease, affects brain function in older adults, and it hopes to find new ways to help improve thinking skills for those living with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $804,450 |
| NIH project number | 1R01AG092390-01 |
| Project ID | NIH-11100623 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are carriers of the APOE4 gene and may be experiencing cognitive decline.
✕Less likely to help
Patients who are younger than 65 or do not carry the APOE4 gene may not receive direct benefits from this research.
What this research studies
This research focuses on understanding the role of the APOE4 gene, a major risk factor for Alzheimer's disease, and how it affects brain function, particularly in older adults. The study aims to explore the relationship between APOE4, GABAergic dysfunction, and cognitive decline, using both animal models and clinical observations. By examining how these factors interact, the research seeks to identify potential therapeutic strategies that could mitigate cognitive impairment in individuals with Alzheimer's disease. Patients may benefit from insights gained about the mechanisms of their condition and potential new treatment options.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve cognitive function and quality of life for Alzheimer's patients carrying the APOE4 gene.
How similar studies have gone: Previous studies have shown promising results in targeting similar pathways in Alzheimer's disease, indicating potential for success in this novel approach.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Zilberter, Misha Yuri — J. David Gladstone Institutes
- Study coordinator: Zilberter, Misha Yuri
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.